Keji Pharmaceutical-B (02171): CT1190B and CT071 abstracts were presented at the 2026 ASH Annual Meeting

Zhitongcaijing · 1d ago

Zhitong Finance App News, Keji Pharmaceutical-B (02171) issued an announcement. A summary of the study results of CT1190B (a generic CAR-T candidate targeting CD19/CD20) to treat relapsed/refractory large B-cell lymphoma, and CT071 (an autologous CAR-T candidate product targeting GPRC5D) to treat recurrent/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM) were summarized at the 68th American Society of Hematology (ASH) Announced at the annual meeting. Research data for the two candidate products will be presented in the form of posters at the ASH annual conference. Research updates on CT0596 (a generic CAR-T candidate product targeting BCMA) for the treatment of R/R MM and primary plasma cell leukemia will be published in a separate company announcement in December 2026.